Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-1.01M | 0.00 | -1.29M | -1.18M | -1.05M | -217.00K | EBIT |
-65.25M | -104.03M | -75.64M | -68.67M | -56.65M | -57.04M | EBITDA |
-64.54M | -104.03M | -74.81M | -65.88M | -55.97M | -56.82M | Net Income Common Stockholders |
-64.90M | -102.02M | -71.17M | -65.45M | -56.41M | -55.84M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
43.16M | 113.09M | 188.59M | 127.87M | 111.80M | 159.90M | Total Assets |
0.00 | 123.18M | 200.85M | 139.19M | 123.54M | 169.36M | Total Debt |
0.00 | 15.41M | 46.59M | 6.78M | 3.37M | 1.29M | Net Debt |
43.16M | -5.67M | 12.00M | -26.14M | -19.95M | -158.61M | Total Liabilities |
0.00 | 65.36M | 60.37M | 20.80M | 14.27M | 11.26M | Stockholders Equity |
41.15M | 57.83M | 140.48M | 118.59M | 109.27M | 158.10M |
Cash Flow | Free Cash Flow | ||||
-54.93M | -91.97M | -70.97M | -58.17M | -48.55M | -36.54M | Operating Cash Flow |
-54.59M | -91.91M | -70.67M | -57.76M | -48.15M | -35.97M | Investing Cash Flow |
22.18M | 67.00M | -53.65M | -5.40M | 42.80M | -117.18M | Financing Cash Flow |
68.82M | 11.40M | 125.97M | 72.79M | 609.00K | 149.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $13.45B | 32.05 | 8.05% | ― | 17.35% | 151.40% | |
52 Neutral | $125.08M | ― | -3758.21% | ― | -99.95% | -5.95% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
49 Neutral | $30.91B | ― | -414.62% | ― | 22.97% | 38.54% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
43 Neutral | $68.09M | ― | -102.90% | ― | ― | -17.06% | |
32 Underperform | $875.43M | ― | -54.14% | ― | ― | 6.99% |
Inozyme Pharma announced positive interim results for its INZ-701 treatment from the ENERGY 1 trial and Expanded Access Program, demonstrating improved survival rates, reduced arterial calcifications, and improved heart function in infants and young children with ENPP1 Deficiency. The company completed enrollment in the ENERGY 3 pivotal trial and received regulatory guidance for the upcoming ASPIRE pivotal trial focused on ABCC6 Deficiency in children, highlighting significant advancements in their therapeutic programs and underscoring the potential impact on addressing unmet medical needs in these patient populations.